Related Experiment Video
Updated: Aug 16, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
Published on: March 17, 2019
The impact of race on response to RAAS inhibition
Thomas W Wallace1, Mark H Drazner
1University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Insights
Angiotensin-converting enzyme (ACE) inhibitors show varied efficacy in Black and White patients with heart failure. While effective for mortality, ACE inhibitors may be less effective for hospitalizations in Black patients compared to White patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Heart failure with reduced ejection fraction affects diverse populations.
- Ethnic variations in treatment response for heart failure are increasingly recognized.
- Angiotensin-converting enzyme (ACE) inhibitors are a standard therapy for heart failure.
Purpose of the Study:
- To evaluate the efficacy of ACE inhibitors in Black versus White patients with heart failure.
- To compare the effectiveness of enalapril and isosorbide dinitrate/hydralazine combinations across ethnic groups.
Main Methods:
- Retrospective analysis of data from the Studies of Left Ventricular Dysfunction (SOLVD) and Vasodilator Heart Failure Trials (V-HeFT).
- Comparison of mortality, heart failure development, and hospitalization rates based on ethnicity and treatment.
Main Results:
- In SOLVD, enalapril reduced mortality and heart failure development similarly in Black and White patients, but reduced hospitalizations more in White patients.
- In V-HeFT II, enalapril reduced mortality more effectively in White patients than isosorbide dinitrate/hydralazine, but not in Black patients.
- Evidence suggests isosorbide dinitrate/hydralazine may be particularly beneficial for Black patients.
Conclusions:
- ACE inhibitors remain a crucial therapy for heart failure with reduced ejection fraction in both Black and White patients.
- Treatment strategies may need ethnic-specific considerations, particularly regarding hospitalization reduction and alternative therapies like isosorbide dinitrate/hydralazine for Black patients.
Abstract:
Retrospective analyses of the Studies of Left Ventricular Dysfunction (SOLVD) and Vasodilator Heart Failure Trials (V-HeFT) have addressed the question of whether angiotensin-converting enzyme (ACE) inhibitors are equally efficacious in black patients and white patients with heart failure. In SOLVD, there was no ethnic difference in the efficacy of enalapril for reducing mortality and preventing the development of heart failure, but enalapril was more effective in whites in reducing hospitalizations. In V-HeFT II, enalapril was more efficacious than the combination of isosorbide dinitrate and hydralazine in whites in reducing mortality, but not in blacks. However, the combination of isosorbide dinitrate and hydralazine may be particularly advantageous in black patients as suggested by V-HeFT I and the recent African American Heart Failure Trial. In aggregate, the available data suggest that ACE inhibitors should remain a cornerstone of therapy for heart failure with a reduced ejection fraction in white patients and black patients.
Related Concept Videos
Stereotypes, Prejudice, and Discrimination
Surveys
Instinctive Drift

